Biomemory, a Paris, France-based provider of DNA data synthesis and storage solutions, raised EUR5M in Seed funding.

The round was led by eureKARE and the French Tech Seed Fund, with participation from Paris Business Angels, and Prunay Impact.

The company intends to use the funds to optimize its technologies.

Founded in 2021 and led by Erfane Arwani, President, Biomemory is a DNA data storage company whose ambition is to help meet the climate challenge posed by data centers, which currently have a carbon footprint greater than civil aviation. The company is developing a petrol-free DNA synthesis and copy process based on synthetic biology, exploiting mechanisms refined over 4 billion years of evolution. Its technologies enable the production of long, bio-sourced, biocompatible and bio-secure DNA fragments that can be stored as inert polymers for thousands of years without any energy input.

Biomemory, through its innovative solutions, currently has the potential to reduce this cost to $1/megabyte. Through further optimization and scaling of its technologies, the company expects it can further reduce costs to $1/terabyte. This compares to the 10-year cost of $17/terabyte for magnetic tapes. To achieve this, Biomemory will focus on miniaturization, automation and parallelization of an end-to-end integrated and continuous microfluidic DNA assembly device.

FinSMEs

28/11/2022